US regulators approve first drug to slow progression of Alzheimer’s


Bankinter| Biotech led falls in the session after the FDA (regulatory agency) approved its Alzheimer’s drug, developed together with Eisai, the first to delay the progression of the disease. The problem came from unexpected testing requirements and side-effect warnings about the drug, which could limit its effective use.

About the Author

The Corner
The Corner has a team of on-the-ground reporters in capital cities ranging from New York to Beijing. Their stories are edited by the teams at the Spanish magazine Consejeros (for members of companies’ boards of directors) and at the stock market news site Consenso Del Mercado (market consensus). They have worked in economics and communication for over 25 years.